Brief: Hansa Biopharma Presents Positive Outcomes Of Study Of Imlifidase In Kidney Transplantation
30/06/2025 07:07
June 30 (Reuters) - Hansa Biopharma AB HNSA.ST: PRESENTS POSITIVE OUTCOMES OF FIVE-YEAR FOLLOW-UP STUDY OF IMLIFIDASE IN KIDNEY TRANSPLANTATION AT ESOT CONGRESS 2025 IN LONDON Source text: ID:nWkr6n32JZ Further company coverage: HNSA.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Hansa Biopharma AB
See all newsBrief: Hansa Biopharma Q3 Rev Up At SEK 143 Mln
Sweden's Hansa Biopharma Q3 revenue surges on SERB license deal
Brief: Hansa Biopharma Q3 Net Income SEK -178.5 Million
Brief: Hansa Biopharma Announces Positive Idefirix Paes Results Presented In The High-Impact Clinical Trials Session At Asn Kidney Week
Brief: Hansa Biopharma Submits IND Application To FDA For HNSA-5487 In GBS